Does Bipolar Disorder Get Worse With Age? Long-Term Course and Outcomes
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Does bipolar disorder get worse with age? There is no universal pattern of progressive deterioration. Some people experience recurrent or increasingly burdensome episodes, while others remain stable for years or find that certain symptoms become less prominent. Aging can also bring changes in physical health, cognition, daily functioning, and medication tolerability that are clinically important even when mood episodes have become less severe. The most accurate answer is that long-term outcomes vary considerably between people and across different dimensions of health. A comprehensive 2026 review of older-age bipolar disorder describes that heterogeneity and the continuing lack of reliable individual prediction models.
The word "worse" may refer to more frequent mania, longer or more severe depression, persistent symptoms between episodes, impaired memory or concentration, reduced ability to work independently, more hospitalizations, or declining quality of life. These are related but distinct outcomes. A person can have fewer manic symptoms in later life and still experience greater medical burden; another can live with a recurrent diagnosis and retain independence and purpose through appropriate treatment and support. Studies that measure one outcome cannot automatically answer questions about another. This article separates the evidence on episodes, depression, cognitive aging, medical health, functioning, and long-term care rather than treating age as a single measure of prognosis.
The clinical message follows from the evidence: recurrence remains possible throughout life, but bipolar disorder is treatable and an individual's future cannot be read from age alone. Long-term care is most useful when it tracks the person's actual episode history, residual symptoms, physical health, treatment effects, and goals. The NICE bipolar guideline describes the condition as having a variable course and provides recommendations for maintenance care across the lifespan.
For additional clinical context, see Bipolar Disorder and Cognitive Function: Memory, Attention, and Daily Life.
The evidence-based answer in brief
Bipolar disorder commonly involves recurrent mood episodes, sometimes separated by substantial periods of remission. It may also involve ongoing subthreshold depressive or hypomanic symptoms that are less visible than acute crises. Historically important prospective research showed that many participants experienced symptoms during a meaningful proportion of follow-up weeks, with depression occupying more time than mania. That research established a considerable illness burden, but it did not prove that symptoms steadily intensify as people grow older. See the long-term bipolar I follow-up study.
More recent international research has found that older age is associated, on average, with lower current manic symptom severity, alongside greater somatic illness burden. Findings for depression have been less consistent, and age did not independently predict worse functioning in one major replication sample. These results do not mean that later life is protective against new episodes. They describe averages in particular research samples, many of which are cross-sectional. The 2024 GAGE-BD replication is especially informative because it found a similar age association for mania but did not reproduce a corresponding association for depression.
A useful answer therefore has three parts: bipolar episodes can recur with age; the severity and frequency of episodes do not inevitably increase with age; and attention to medical illness, medication safety, cognition, and functioning becomes increasingly important. Decisions about prevention and treatment depend on clinical history and contemporary guidelines, not a presumed stage of unavoidable decline. NICE CG185 and the 2023 CANMAT/ISBD evidence update provide the principal treatment framework.
What counts as bipolar disorder getting worse?
A clinician evaluating the long-term course may consider the number of distinct mood episodes per year, episode duration, the intensity of depression or mania, psychotic or mixed features, suicidal thoughts, time required for recovery, persistent symptoms between episodes, and functional consequences. An episode can be severe because it disrupts judgment, creates a safety risk, requires hospitalization, or produces profound disability. Frequency, severity, and consequences can move in different directions. NIMH's clinical overview explains the nature of manic, hypomanic, and depressive episodes and the need to consider their course.
Bipolar I disorder includes at least one lifetime manic episode. Bipolar II requires hypomania and major depression without a history of full mania. Hypomania and mania differ in severity and impairment; hypomania does not by itself cause the marked impairment or hospitalization characteristic of mania, and psychosis indicates mania. Bipolar II is not simply a mild form of bipolar I, because depression and functional impairment can be substantial. Cyclothymic disorder involves a longer pattern of fluctuating symptoms that do not meet full episode criteria over the relevant period. These diagnostic differences matter when comparing prognosis studies that recruit dissimilar groups. NIMH provides a clinically grounded introduction.
Recurrence means that a new episode occurs after a period of recovery; relapse usually refers to a return of illness before a sufficient recovery period has been established. Remission concerns a sustained reduction or absence of episode symptoms. Functional recovery concerns everyday activity and relationships, which may take longer than symptomatic remission. Someone who is euthymic today may nonetheless need continued treatment to reduce the probability of future episodes. Further distinctions are covered in Bipolar Disorder Recovery and Remission.
Age-related progression also needs to be distinguished from the cumulative lifetime number of episodes. Someone living with bipolar disorder for 30 years has had more time to experience an episode than someone followed for three years, even if the annual recurrence rate has remained unchanged. A research paper reporting more past episodes in older participants therefore does not necessarily show that episodes have become more frequent each successive year. Longitudinal designs that repeatedly observe the same people are better suited to that question than one-time comparisons. The 2026 older-age review discusses these methodological differences.
What do long-term studies actually show?
Prospective observations of bipolar I disorder
One landmark study prospectively examined the weekly symptomatic status of 146 people with bipolar I disorder over a mean follow-up of 12.8 years. Participants had mood symptoms during 47.3% of observed weeks. Depressive symptoms were recorded during 31.9% of weeks, while manic or hypomanic symptoms occurred during a smaller percentage. Subthreshold symptoms accounted for a substantial portion of the illness burden. This result shows why a person's long-term experience may not be adequately captured by counting severe manic episodes alone. It does not establish that 47.3% is the expected lifetime course for everyone or that symptom burden accelerates with age. See Judd et al., 2002.
The cohort was recruited decades ago, and the study used the diagnostic and treatment context of its era. Treatment choices, clinical recognition, access to care, and diagnostic definitions have changed. A long-follow-up study remains highly valuable for measuring repeated symptoms within people, but its descriptive percentages should not be presented as a prediction for someone receiving contemporary treatment. Its strongest lesson is that depressive and subthreshold states deserve systematic follow-up even when full mania is uncommon. Judd et al., 2002.
Prospective observations of bipolar II disorder
A related study prospectively followed 86 participants with bipolar II disorder for a mean of 13.4 years. Depressive symptoms were prominent, including periods beneath the threshold for a full major depressive episode. The findings support careful attention to the depressive burden of bipolar II rather than treating hypomania as the sole measure of illness. They also reinforce the point that bipolar I and bipolar II should not be collapsed into a single undifferentiated long-term course. Judd et al., 2003.
Neither historical follow-up demonstrates that all people with bipolar II eventually develop bipolar I or that symptom severity necessarily rises with every subsequent episode. A lifetime manic episode would change the diagnostic classification, but this possible clinical event is not the same as an inevitable age-related transition. Accurate assessment depends on episode history, duration, impairment, substance and medication effects, and alternative explanations. The NIMH bipolar disorder overview outlines the diagnostic distinctions.
Why long studies and age comparisons answer different questions
Prospective follow-up reveals how individuals change. Cross-sectional analysis reveals how older and younger participants differ at one point. Those differences might reflect aging, but also birth cohort, health status, treatment history, survivorship, recruitment differences, and who remains able to participate in research. Attrition can make people with more difficult illness courses less visible in long studies. The international GAGE-BD replication used pooled data to improve sample size, while the 2026 synthesis emphasizes that genuinely prospective lifespan evidence remains essential.
Does mania become more frequent or severe as people age?
The available evidence does not demonstrate inevitable age-related escalation of mania. In the GAGE-BD replication, older age was associated with less severe current manic symptoms, an association consistent with the project's earlier pooled analysis. This is a population average, not a guarantee that a person who has reached 50 or 70 will stop having manic episodes. Mania can recur after years of stability and can present serious risks at any age. Sajatovic et al., 2024.
An older person experiencing severe agitation, greatly reduced need for sleep, unusual activity, grandiose beliefs, major spending changes, impulsive decisions, or psychosis needs assessment based on the current presentation. Medication effects and medical conditions may complicate or imitate some psychiatric symptoms, especially later in life. Reduced average mania scores in research do not lower the importance of identifying serious episodes or impaired judgment. NICE advises urgent referral for suspected mania and attention to immediate safety. NICE recommendations.
Research also distinguishes a person's lifetime episode count from the polarity and severity of recent symptoms. An earlier history of severe mania may still affect social, occupational, financial, and health outcomes even when episodes are less frequent now. Treatment can reduce recurrence risk, while residual consequences may require separate support. The 2026 review frames older-age functioning as a combination of mood symptoms, physical illness, and cognitive health.
Does bipolar depression get worse with age?
Depression is a major contributor to bipolar disorder's long-term burden, but its age trajectory remains uncertain. In one pooled GAGE-BD dataset, older participants had lower average depression scores; in an independent replication, age was not associated with depression severity. The inconsistent result matters. It prevents the conclusion that depression reliably intensifies with age, and it also prevents the claim that bipolar depression naturally disappears in later life. See the initial GAGE-BD analysis and 2024 replication.
A depressive presentation in later life may coexist with bereavement, isolation, physical illness, pain, disrupted sleep, medication adverse effects, and cognitive changes. A clinician must determine whether symptoms form a new bipolar depressive episode, represent persistent residual symptoms, or arise partly from other conditions. Serious depression can involve inability to function, poor nutrition, inability to care for oneself, or suicidal thoughts. Longitudinal history and careful assessment remain essential regardless of age. NICE recommends phase-specific assessment and treatment.
Treatment evidence for bipolar depression cannot be copied wholesale from unipolar depression or acute mania. Decisions about medications, psychological interventions, and monitoring are guided by the clinical phase and individual risks. The CANMAT/ISBD evidence update and VA/DoD bipolar guideline distinguish acute bipolar depression from mania and maintenance prevention.
How may the course differ across adulthood?
Early adulthood: episodes, recognition, and establishing continuity
Bipolar disorder often emerges or becomes clinically evident in adolescence and early adulthood, although age of onset varies and some people are diagnosed much later. At this stage, diagnosis may require reconstructing earlier elevated mood periods, depressive episodes, medication exposure, sleep patterns, and changes in functioning. Some people first seek care for depression and only later disclose or recognize past hypomania. Screening instruments can support a clinical conversation, but diagnostic decisions require more than a score. NIMH describes the importance of symptoms, history, and clinical evaluation.
Young adulthood may also involve changes in education, work, relationships, living arrangements, and sleep routines. Those transitions influence access to care and how symptoms affect daily life. Tracking early warning signs and responses to treatment provides a stronger basis for later decision-making than assuming that a difficult first episode determines the entire lifespan. NICE's long-term care guidance emphasizes collaborative plans and ongoing review.
Midlife: long history, physical health, and functional demands
By the 40s and 50s, clinicians may be reviewing decades of illness history or a prolonged period of successful maintenance. Some people have accumulated consequences from past episodes; others have built reliable systems for prevention and recovery. Concurrent cardiovascular, metabolic, renal, thyroid, or other conditions can become increasingly relevant, as can work, caring responsibilities, social changes, and access to appropriate services. A worsening of fatigue, concentration, or function should be evaluated rather than automatically attributed to bipolar progression. NICE recommends physical-health monitoring and regular review of treatment effects.
Older age: a distinct set of care needs, not an inevitable endpoint
Research commonly defines older-age bipolar disorder using a threshold of 50 years, though individual studies vary, and this is a research convention rather than a new diagnostic category. Most people in older-age cohorts developed bipolar disorder earlier in life; a smaller proportion have apparent onset after 50. The 2026 review reports potentially reduced current mood symptom severity alongside increased somatic and cognitive burden, stressing substantial individual variation.
A clinician caring for an older adult may need to evaluate fall risk, mobility, medication interactions, kidney function, cognition, hearing or vision problems, medical illness, and changes in social support. The aim is to preserve stability and independence while recognizing the full person rather than treating every age-related difficulty as part of bipolar illness. The NICE guideline specifically recommends that older adults be offered the same range of bipolar services as younger adults, with medication choices adapted to their medical and cognitive circumstances. NICE CG185.
Does bipolar disorder cause faster cognitive aging?
Some people with bipolar disorder experience difficulties with processing speed, attention, working memory, or executive functioning, including during periods without major mood episodes. Research also shows diverse cognitive outcomes. Lower average test performance in a group does not necessarily mean that every individual deteriorates faster year after year. Cognitive trajectories may include stable differences from comparison groups, ordinary aging from a different starting point, faster deterioration in a subgroup, or changes influenced by another medical or neurocognitive disorder. The 2026 scientific synthesis emphasizes these possibilities and their unresolved mechanisms.
Interpretation depends on the exact test and time frame. Memory, concentration, verbal ability, planning, and processing speed are not interchangeable. Depression can impair concentration; sedating medications may affect alertness; sleep loss, thyroid problems, substance exposure, and other health conditions may contribute to symptoms. A patient reporting poorer concentration after a medication change needs a clinical medication and health review, not an automatic conclusion of irreversible neuronal injury. Older-age longitudinal cognition research illustrates the challenges of small cohorts and different outcome measures. Gildengers et al., 2009.
The term "neuroprogression" is used in research on possible changes in cognition, brain structure, and biological processes over illness course. It is a hypothesis and framework, not a validated bedside test that establishes progressive damage in every person with bipolar disorder. Observed links between episode history and cognitive measures can be affected by illness severity, medication, education, medical comorbidity, and other variables. The 2026 review calls for more prospective research to identify which patients, if any, have accelerated decline and which interventions improve outcomes.
When a person develops new memory loss, confusion, difficulty with familiar tasks, or major changes in judgment, clinical evaluation should consider depression, mania, medications, sleep, neurological illness, delirium, and possible neurocognitive disorder. Acute confusion is particularly important because it can indicate a medical emergency. A diagnosis of bipolar disorder should never prevent a separate assessment of new cognitive symptoms. The evidence on cognition concerns the long-term course; specialized cognitive questions are a separate reserved English Hub node not yet publicly linked.
Does bipolar disorder increase the risk of dementia?
Some epidemiological studies report an association between a history of bipolar disorder and later dementia diagnosis. Associations of this kind deserve attention, but they do not demonstrate that bipolar illness directly causes dementia in each affected person. Shared vascular risks, medical disorders, treatment exposures, differences in diagnostic surveillance, and other confounding factors may influence observational estimates. Moreover, longitudinal studies of actual cognitive change do not all show accelerated deterioration in every bipolar cohort. The 2026 older-age review discusses the conflicting evidence.
The practical response is careful assessment of new cognitive problems and management of modifiable general-health risks. Dementia, delirium, medication effects, bipolar depression, and persistent cognitive difficulties have different diagnostic implications and care pathways. No reader should infer dementia from bipolar diagnosis, a single memory complaint, or an online test. If confusion develops suddenly, prompt medical evaluation is appropriate because the cause may be treatable and time-sensitive. NICE's older-adult and medication recommendations support coordinated attention to cognition and comorbid medical illness.
Can physical health worsen even when mood symptoms improve?
Yes. Physical health and current mood severity are distinct dimensions. In the independent GAGE-BD replication, older participants had greater somatic burden and lower current manic symptom severity; age was not associated with poorer functioning in that cohort. More severe current mania and depression, however, were associated with worse functioning. This combination shows why global claims such as "bipolar disorder gets worse with age" obscure important differences among outcomes. Sajatovic et al., 2024.
Long-term care needs to address cardiovascular and metabolic risks, blood pressure, weight, diabetes risk where relevant, smoking and substance use, physical activity suited to capacity, and monitoring for medication effects. A person's physical health may change because of age, a preexisting condition, psychiatric symptoms, treatment, or several causes together. Identifying these mechanisms is more useful than assuming the illness itself has inevitably advanced. The NICE monitoring recommendations cover relevant medication-related and physical-health checks.
What predicts a more difficult long-term outlook?
Risk is best understood as a pattern of information rather than a deterministic score. Past severe or frequent mood episodes, persistent depressive symptoms, previous hospitalization, substance-related problems, difficulties accessing sustained treatment, and substantial impairment may help clinicians identify areas requiring closer monitoring. Yet associations do not tell a particular individual how many episodes they will experience over the next decade. Historical longitudinal symptom studies show significant variation, and modern reviews underline the limits of prediction. Judd et al., 2002; Eyler et al., 2026.
Disruption of sleep and daily rhythms may be a practical warning sign for someone whose previous episodes began with changing sleep needs or activity. Other people notice shifts in speech, spending, social behavior, energy, irritability, or depression. A warning sign is a reason to monitor or contact the care team; it does not establish a new manic or depressive episode by itself. A guide to individualized observation appears in Early Warning Signs of Mania and Bipolar Relapse.
The strongest prediction may be that a person's needs will change over time. New medical conditions, reduced access to services, bereavement, major responsibilities, social isolation, and treatment adverse effects can alter functioning without reflecting a progressively degenerative psychiatric process. Evaluating these factors enables practical interventions, accommodations, and treatment reviews. NICE's recommendations support individualized planning and ongoing collaboration.
What about first-time mania after age 50?
A first apparent manic episode in later life merits particular attention to differential diagnosis. Clinicians assess whether a person has an earlier, unrecognized mood-episode history and whether medicines, substances, endocrine disease, neurological disease, or another medical condition may account for symptoms. A new psychiatric symptom should not be presumed to arise from age alone. The international older-age bipolar literature describes late-onset presentations as heterogeneous and emphasizes comprehensive evaluation. Eyler et al., 2026.
Medical investigation is especially important if a person suddenly becomes confused or develops pronounced behavioral change, hallucinations, or a major loss of functioning. Delirium, intoxication, neurological disease, and medication toxicity may require urgent treatment. History from family or close supporters, when obtained appropriately, can help establish the baseline and timing of symptoms, but only a qualified clinician can determine the diagnosis. NICE specifies assessment and referral pathways.
Can treatment change the long-term course?
Effective management aims to relieve acute episodes, reduce recurrence, address residual symptoms, prevent harms, and support daily functioning. Maintenance care is a distinct phase of treatment. A drug that treats acute mania does not automatically have equal evidence for acute bipolar depression; benefit in one phase does not establish benefit in preventing all future episodes. The 2023 CANMAT/ISBD evidence update separates recommendations by phase, and the VA/DoD 2023 guideline provides another evidence-based framework.
Lithium has a substantial evidence base as a long-term relapse-prevention medication and is recommended by NICE as a first-line maintenance treatment for many patients, with blood-level and medical monitoring. Other options, including certain antipsychotics, lamotrigine, or other mood-stabilizing medicines, may be considered according to the person's episode pattern, treatment response, comorbidities, and safety needs. The effectiveness and risks of these options differ. The specific long-term pharmacological evidence is covered in Bipolar Maintenance Treatment, alongside NICE.
Psychotherapy and psychoeducation can support recognition of early warning signs, routine building, family communication, adherence, problem-solving, and personal recovery. Clinical decisions need to reflect what the person values, alongside the phase of illness and the best applicable evidence. Structured support may complement medication rather than replace an indicated maintenance regimen. More detail about the full treatment system is available in Bipolar Disorder Treatment: Medication, Therapy, and Long-Term Care.
A period of stability is not proof that relapse risk has disappeared. Discontinuation or medication switching should be planned with a qualified prescriber who can weigh previous course, benefits, adverse effects, and alternative strategies. Suddenly stopping a long-term medication may increase relapse risk. NICE calls for discussion of recurrence risk before medication reduction and appropriate monitoring during change. NICE guideline.
Medication safety as patients grow older
Medication choice deserves periodic reassessment when kidney function, thyroid status, weight, blood pressure, other prescriptions, or fall risk change. For lithium, monitoring includes serum levels and relevant renal, thyroid, calcium, and electrolyte measurements. Dehydration, acute illness, and interactions with certain commonly used drugs can increase toxicity risk. NICE recommends lithium levels at least every three months in older people and extra medical review when renal function or other safety markers change. New confusion, marked unsteadiness, severe tremor, vomiting, or diarrhea may warrant urgent evaluation. NICE lithium guidance.
Antipsychotics can differ in risks involving weight, blood sugar, lipids, movement disorders, sedation, blood pressure, and falls. Lamotrigine requires careful prescribing and attention to potentially serious new rashes, especially during titration. Valproate has important reproductive, hepatic, and metabolic risks and country-specific restrictions, making individual safety assessment essential. Antidepressants may contribute to mood switching or destabilization in some patients; they are not an interchangeable substitute for phase-specific bipolar care. CANMAT/ISBD and NICE discuss clinical selection and medication monitoring.
Older adults may be particularly susceptible to drug interactions, sedation, and anticholinergic effects that interfere with cognition or mobility. NICE recommends accounting for these effects when selecting treatment and ensuring coexisting medical conditions are evaluated. Never start, stop, or change a prescribed psychiatric medicine on the basis of generalized online information; a medication review should address the individual's risks, current medicines, medical tests, treatment response, and preferences. NICE CG185.
How can patients and families recognize meaningful change?
Record changes over time, not merely dramatic memories of crises. Useful information may include the dates and duration of past episodes, sleep and activity changes, hospitalizations, residual depressive symptoms, medicine adjustments, relevant physical illnesses, and months of stable functioning. The same measures assessed at successive appointments may show whether the current concern is an increase in annual recurrence frequency, longer recovery, worsening function, new medical illness, or medication adverse effects. NIMH describes the importance of longitudinal history for bipolar assessment.
Family members can share concrete observations with the person's consent: a changed sleep pattern, new confusion, marked behavioral shifts, or inability to manage previously familiar tasks. Respectful communication focuses on observable changes and what support is welcome rather than labeling ordinary disagreement or emotion as a symptom. A care plan can specify which changes prompt a routine appointment, rapid contact with a specialist, or urgent evaluation. NICE recommends collaborative care planning and support for carers.
Long-term planning should include ordinary preventive medical care, regular medication review, realistic sleep and daily-life routines, and social support. The goal is to preserve autonomy and meaningful participation rather than to seek a mythical age at which the disorder becomes permanently harmless. Symptoms can recur, but people can also sustain long periods of wellness and functioning. Eyler et al., 2026 emphasizes the importance of lifespan-oriented, individualized care.
When a change requires urgent help
Severe mania, psychosis, rapidly escalating agitation or disinhibition, dangerous impairment in judgment, inability to meet basic needs, or severe depression with suicidal thoughts requires urgent professional assessment. The immediate clinical situation determines urgency, not a person's age. NICE recommends urgent specialist assessment for suspected mania and for severe depression or risks to safety. NICE recommendations.
If there is immediate danger, contact local emergency services or the nearest emergency department. In the United States, people can call or text 988 for the Suicide & Crisis Lifeline; outside the United States, use local emergency and crisis services. Sudden confusion or suspected lithium toxicity also warrants urgent medical evaluation. More detailed information about safety planning is available in Bipolar Disorder and Suicide Risk.
What researchers still need to establish
The strongest current evidence supports a recurrent but diverse clinical course. Important questions remain about which individuals experience worsening mood symptoms, accelerated cognitive change, declining function, or an increased physical-health burden. Studies often differ in recruitment, psychiatric diagnoses, measures, follow-up duration, medication exposure, and how they account for medical comorbidity. Results from cross-sectional older-versus-younger comparisons cannot automatically be read as within-person change. The 2026 older-age review identifies large, inclusive, prospective cohorts and better prediction models as key needs.
Research on inflammation, oxidative stress, neuroimaging, and other possible biological pathways is active, but these mechanisms are not yet reliable individual clinical tests of whether bipolar disorder will worsen with age. People deserve an assessment based on real episodes, functioning, health status, and treatment response rather than speculative biological age labels. The clinical priorities remain evidence-based prevention, appropriate assessment of new symptoms, and coordinated medical and mental-health care. Eyler et al., 2026.
Frequently asked questions
Can bipolar disorder improve after age 50?
Some studies report lower average current manic symptom severity in older participants, but this does not establish that untreated bipolar disorder naturally improves after 50. Depression results are inconsistent and recurrence remains possible. Maintenance needs should be reviewed individually. Sajatovic et al., 2024.
Does bipolar disorder become more severe every time an episode returns?
There is no universal rule that each episode is more severe than the previous one. Episodes can differ in polarity, severity, duration, symptoms, and consequences. Past episodes can influence clinical risk assessment, but a rising lifetime count is not proof of accelerating illness. Judd et al., 2002.
Can someone with bipolar disorder live a normal lifespan and remain independent?
People with bipolar disorder have highly varied health and functional outcomes, including long periods of stability and meaningful independence. Medical comorbidities and elevated population-level health risks deserve attention, and an individual prognosis depends on many factors. Ongoing treatment and preventive health care are important. Eyler et al., 2026.
Does bipolar II inevitably change into bipolar I later in life?
No. A later full manic episode would change the diagnostic classification to bipolar I, but this is not an inevitable age-related stage. A careful clinical history is required to distinguish a manic episode from hypomania, medication or substance effects, and other explanations. NIMH.
Does bipolar disorder cause dementia?
Some observational research has found an association with later dementia, but bipolar disorder is not equivalent to dementia and does not establish inevitable cognitive decline in every person. New memory or thinking problems need assessment for multiple potential causes. Eyler et al., 2026.
Why might an older person have less mania but more difficulty with everyday life?
Mood symptoms, physical illness, cognition, and functional demands can change independently. Somatic illness burden was greater in older participants in a large GAGE-BD replication, even while current mania symptoms were lower on average. The individual's difficulties should be evaluated specifically. Sajatovic et al., 2024.
Is it safe to stop bipolar medication after years without an episode?
Years of stability do not show that maintenance treatment is no longer needed. Recurrence risk, prior episode severity, safety, physical-health monitoring, and the person's preferences should be discussed with the prescriber before any planned change. Abrupt self-directed discontinuation is unsafe. NICE.
How often should bipolar disorder be reviewed in later life?
The schedule depends on stability, treatment, risks, and medical conditions. NICE recommends at least annual comprehensive review and more frequent monitoring as clinically indicated. Older adults taking lithium require more frequent serum monitoring and ongoing renal and thyroid assessments. NICE CG185.
Related Articles
References
Eyler, L. T., Klaus, F., Van Dyne, A., Ng, H. X., Dols, A., & Sajatovic, M. (2026). The spectrum of bipolar disorder in older adults. Neuropsychopharmacology. https://doi.org/10.1038/s41386-026-02330-4
Gildengers, A. G., et al. (2009). The longitudinal course of cognition in older adults with bipolar disorder. Bipolar Disorders, 11(7), 744–752. Bipolar Disorders. https://pubmed.ncbi.nlm.nih.gov/19719787/
Judd, L. L., Akiskal, H. S., Schettler, P. J., et al. (2002). The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry, 59(6), 530–537. https://doi.org/10.1001/archpsyc.59.6.530
Judd, L. L., Akiskal, H. S., Schettler, P. J., et al. (2003). A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder. Archives of General Psychiatry, 60(3), 261–269. https://doi.org/10.1001/archpsyc.60.3.261
Keramatian, K., Chithra, N. K., & Yatham, L. N. (2023). The CANMAT and ISBD guidelines for the treatment of bipolar disorder: Summary and a 2023 update of evidence. Focus, 21(4), 344–353. https://doi.org/10.1176/appi.focus.20230009
National Institute for Health and Care Excellence. (2025). Bipolar disorder: Assessment and management (CG185; updated September 2, 2025). https://www.nice.org.uk/guidance/cg185/chapter/recommendations
National Institute of Mental Health. (n.d.). Bipolar disorder. https://www.nimh.nih.gov/health/publications/bipolar-disorder
Sajatovic, M., et al. (2021). Bipolar symptoms, somatic burden, and functioning in older-age bipolar disorder: GAGE-BD pooled analyses. https://pubmed.ncbi.nlm.nih.gov/34314549/
Sajatovic, M., et al. (2024). Bipolar symptoms, somatic burden and functioning in older-age bipolar disorder: A replication study from the GAGE-BD project. International Journal of Geriatric Psychiatry, 39(3), e6057. https://doi.org/10.1002/gps.6057
U.S. Department of Veterans Affairs and Department of Defense. (2023). VA/DoD clinical practice guideline for the management of bipolar disorder. https://healthquality.va.gov/HEALTHQUALITY/guidelines/mh/bd/index.asp